文献速递银屑病与炎症性皮肤病

细胞疗法治疗银屑病的前景与挑战

The promise and challenges of cell therapy for psoriasis.
PubMed 文献 · Br J Dermatol · 2021-07-27

中重度银屑病管理因生物制剂而改变,但部分患者对所有现有疗法失败。本综述讨论细胞疗法(包括造血干细胞移植和间充质基质细胞)在免疫介导炎症性疾病中的应用及在难治性银屑病中的新兴证据,强调需平衡风险与获益,并呼吁设计良好的对照试验。

要点

  • 生物制剂使多数银屑病患者皮损清除,但非治愈且部分患者治疗失败。
  • 细胞疗法在难治性免疫介导炎症性疾病中已有应用,银屑病证据有限。
  • 间充质基质细胞和调节性T细胞等低风险细胞疗法可能更适用于银屑病。

核心结论

  • 细胞疗法对难治性银屑病有前景但风险高,需设计良好的对照试验验证。

研究设计与样本

  • 综述,讨论细胞疗法在免疫介导炎症性疾病及难治性银屑病中的证据。

主要发现

  • 生物制剂可使多数银屑病患者皮损清除或近乎清除,但非治愈。
  • 少数重度银屑病患者对所有现有疗法失败。
  • 造血干细胞移植有 anecdotal 报告改善重度银屑病,有时明显治愈,但多在其他常规适应症背景下。

临床怎么用

  • 细胞疗法风险、成本、监管复杂,需权衡风险获益,仅用于难治性患者。
  • 银屑病可能更适合低并发症风险的细胞疗法如间充质基质细胞和调节性T细胞。

局限性

  • 细胞疗法在银屑病中的证据多为 anecdotal,缺乏设计良好的对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of moderate-to-severe psoriasis has been transformed by the introduction of biological therapies. These medicines, particularly those targeting interleukin (IL)-17 and IL-23p19, can offer clear or nearly clear skin for the majority of patients with psoriasis, with good long-term drug survival. However, as currently used, none of these therapies is curative and disconcertingly there is a small but increasing number of patients with severe psoriasis who have failed all currently available therapeutic modalities. A similar scenario has occurred in other immune-mediated inflammatory diseases (IMIDs) where treatment options are limited in severely affected patients. In these cases, cell therapy, including haematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cells (MSC), has been utilized. This review discusses the various forms of cell therapy currently available, their utility in the management of IMIDs and emerging evidence for efficacy in severe psoriasis that is unresponsive to biological therapy. Balancing the risks and benefits of treatment vs. the underlying disease is key; cell therapy carries significant risks, costs, regulation and other complexities, which must be justified by outcomes. Although HSCT has anecdotally been reported to benefit severe psoriasis, sometimes with apparent cure, this has mainly been in the setting of other coincidental 'routine' indications. In psoriasis, cell therapies, such as MSC and regulatory T cells, with a lower risk of complications are likely to be more appropriate. Well-designed controlled trials coupled with mechanistic studies are warranted if advanced cell therapies are to be developed and delivered as a realistic option for severe psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lwin SM, Snowden JA, Griffiths CEM, et al. The promise and challenges of cell therapy for psoriasis. Br J Dermatol. 2021. PMID: 34036569. doi:10.1111/bjd.20517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。